BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dimitroulopoulos D, Xinopoulos D, Tsamakidis K, Zisimopoulos A, Andriotis E, Panagiotakos D, Fotopoulou A, Chrysohoou C, Bazinis A, Daskalopoulou D, Paraskevas E. Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: Randomized placebo-controlled trial. World J Gastroenterol 2007; 13(23): 3164-3170 [PMID: 17589893 DOI: 10.3748/wjg.v13.i23.3164] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Martino MCD, Hofland LJ, Lamberts SW. Somatostatin and Somatostatin Receptors: from Basic Concepts to Clinical Applications. Neuroendocrinology - Pathological Situations and Diseases. Elsevier; 2010. pp. 255-80. [DOI: 10.1016/s0079-6123(10)82011-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
2 Reynaert H, Colle I. Treatment of Advanced Hepatocellular Carcinoma with Somatostatin Analogues: A Review of the Literature. Int J Mol Sci 2019;20:E4811. [PMID: 31569719 DOI: 10.3390/ijms20194811] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
3 Morgan TR. Chemoprevention of hepatocellular carcinoma in chronic hepatitis C. Recent Results Cancer Res. 2011;188:85-99. [PMID: 21253791 DOI: 10.1007/978-3-642-10858-7_7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
4 Rahbari NN, Mehrabi A, Mollberg NM, Müller SA, Koch M, Büchler MW, Weitz J. Hepatocellular Carcinoma: Current Management and Perspectives for the Future. Annals of Surgery 2011;253:453-69. [DOI: 10.1097/sla.0b013e31820d944f] [Cited by in Crossref: 282] [Cited by in F6Publishing: 170] [Article Influence: 25.6] [Reference Citation Analysis]
5 Massironi S, Fraquelli M, Paggi S, Sangiovanni A, Conte D, Sciola V, Ciafardini C, Colombo M, Peracchi M. Chromogranin A levels in chronic liver disease and hepatocellular carcinoma. Dig Liver Dis. 2009;41:31-35. [PMID: 18762462 DOI: 10.1016/j.dld.2008.05.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
6 Msaouel P, Galanis E, Koutsilieris M. Somatostatin and somatostatin receptors: implications for neoplastic growth and cancer biology. Expert Opin Investig Drugs 2009;18:1297-316. [PMID: 19678799 DOI: 10.1517/13543780903176399] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
7 Hsu C, Shen Y, Cheng C, Hu F, Cheng A. Geographic difference in survival outcome for advanced hepatocellular carcinoma: Implications on future clinical trial design. Contemporary Clinical Trials 2010;31:55-61. [DOI: 10.1016/j.cct.2009.08.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
8 Evangelou I, Petraki C, Msaouel P, Scorilas A, Sdrolia E, Padazi G, Koborozos V, Koutsilieris M. Immunohistochemical expression of somatostatin receptor subtypes 2 and 5 in colorectal cancer. Eur J Clin Invest 2012;42:777-83. [PMID: 22304674 DOI: 10.1111/j.1365-2362.2012.02648.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
9 Yopp AC, Jarnagin WR. Randomized Clinical Trials in Hepatocellular Carcinoma. Surgical Oncology Clinics of North America 2010;19:151-62. [DOI: 10.1016/j.soc.2009.09.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
10 Sim HW, Knox J, Dawson LA. An Update on Randomized Clinical Trials in Hepatocellular Carcinoma. Surg Oncol Clin N Am 2017;26:647-66. [PMID: 28923223 DOI: 10.1016/j.soc.2017.05.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
11 Germano D, Daniele B. Systemic therapy of hepatocellular carcinoma: Current status and future perspectives. World J Gastroenterol 2014; 20(12): 3087-3099 [PMID: 24696596 DOI: 10.3748/wjg.v20.i12.3087] [Cited by in CrossRef: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.5] [Reference Citation Analysis]
12 Liu J, Mittendorf T, von der Schulenburg JM. A structured review and guide through studies on health-related quality of life in kidney cancer, hepatocellular carcinoma, and leukemia. Cancer Invest 2010;28:312-22. [PMID: 19863345 DOI: 10.3109/07357900903287022] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
13 Cabibbo G, Enea M, Attanasio M, Bruix J, Craxì A, Cammà C. A meta-analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma. Hepatology. 2010;51:1274-1283. [PMID: 20112254 DOI: 10.1002/hep.23485] [Cited by in Crossref: 249] [Cited by in F6Publishing: 230] [Article Influence: 20.8] [Reference Citation Analysis]
14 Barbare JC, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer. 2009;45:1788-1797. [PMID: 19303768 DOI: 10.1016/j.ejca.2009.02.018] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.2] [Reference Citation Analysis]
15 Schöniger-Hekele M, Kettenbach J, Peck-Radosavljevic M, Müller C. Octreotide treatment of patients with hepatocellular carcinoma--a retrospective single centre controlled study. J Exp Clin Cancer Res 2009;28:142. [PMID: 19887008 DOI: 10.1186/1756-9966-28-142] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Gandhi S, Khubchandani S, Iyer R. Quality of life and hepatocellular carcinoma. J Gastrointest Oncol. 2014;5:296-317. [PMID: 25083303 DOI: 10.3978/j.issn.2078-6891.2014.046] [Cited by in F6Publishing: 26] [Reference Citation Analysis]
17 Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19. [PMID: 20196864 DOI: 10.1186/1756-9966-29-19] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 6.8] [Reference Citation Analysis]
18 Ji XQ, Ruan XJ, Chen H, Chen G, Li SY, Yu B. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials. Med Sci Monit. 2011;17:RA169-RA176. [PMID: 21804474 DOI: 10.12659/msm.881892] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
19 Eychenne R, Bouvry C, Bourgeois M, Loyer P, Benoist E, Lepareur N. Overview of Radiolabeled Somatostatin Analogs for Cancer Imaging and Therapy. Molecules 2020;25:E4012. [PMID: 32887456 DOI: 10.3390/molecules25174012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
20 Baldelli R, Barnabei A, Rizza L, Isidori AM, Rota F, Di Giacinto P, Paoloni A, Torino F, Corsello SM, Lenzi A, Appetecchia M. Somatostatin analogs therapy in gastroenteropancreatic neuroendocrine tumors: current aspects and new perspectives. Front Endocrinol (Lausanne). 2014;5:7. [PMID: 24570674 DOI: 10.3389/fendo.2014.00007] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 4.4] [Reference Citation Analysis]
21 Kaemmerer D, Schindler R, Mußbach F, Dahmen U, Altendorf-Hofmann A, Dirsch O, Sänger J, Schulz S, Lupp A. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets. BMC Cancer 2017;17:896. [PMID: 29282035 DOI: 10.1186/s12885-017-3911-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
22 Periferakis A, Tsigas G, Periferakis AT, Badarau IA, Scheau AE, Tampa M, Georgescu SR, Didilescu AC, Scheau C, Caruntu C. Antitumoral and Anti-inflammatory Roles of Somatostatin and Its Analogs in Hepatocellular Carcinoma. Anal Cell Pathol (Amst) 2021;2021:1840069. [PMID: 34873567 DOI: 10.1155/2021/1840069] [Reference Citation Analysis]
23 Ray EM, Sanoff HK. Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. J Hepatocell Carcinoma 2017;4:131-8. [PMID: 29184856 DOI: 10.2147/JHC.S124366] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
24 Feun LG, Wangpaichitr M, Li YY, Kwon D, Richman SP, Hosein PJ, Savaraj N. Phase II trial of SOM230 (pasireotide LAR) in patients with unresectable hepatocellular carcinoma. J Hepatocell Carcinoma 2018;5:9-15. [PMID: 29392123 DOI: 10.2147/JHC.S153672] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
25 Chen X, Zhang XY, Shen Y, Fan LL, Ren ML, Wu YP. Synthetic paclitaxel-octreotide conjugate reversing the resistance of A2780/Taxol to paclitaxel in xenografted tumor in nude mice. Oncotarget 2016;7:83451-61. [PMID: 27825139 DOI: 10.18632/oncotarget.13120] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
26 Maida M, Cabibbo G, Brancatelli G, Genco C, Alessi N, Genova C, Romano P, Raineri M, Giarratano A, Midiri M. Assessment of treatment response in hepatocellular carcinoma: a review of the literature. Future Oncol. 2013;9:845-854. [PMID: 23718305 DOI: 10.2217/fon.13.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
27 Abdel-Rahman O, Lamarca A, Valle JW, Hubner RA. Somatostatin receptor expression in hepatocellular carcinoma: prognostic and therapeutic considerations. Endocr Relat Cancer. 2014;21:R485-R493. [PMID: 25336571 DOI: 10.1530/erc-14-0389] [Cited by in Crossref: 17] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
28 Caraglia M, Giuberti G, Marra M, Addeo R, Montella L, Murolo M, Sperlongano P, Vincenzi B, Naviglio S, Prete SD. Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR. Cell Death Dis. 2011;2:e150. [PMID: 21525937 DOI: 10.1038/cddis.2011.34] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
29 Treiber G, Wex T, Malfertheiner P. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer. J Cancer Res Clin Oncol 2009;135:271-81. [PMID: 18642029 DOI: 10.1007/s00432-008-0443-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
30 Rodon J, DeSantos V, Ferry RJ, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther. 2008;7:2575-2588. [PMID: 18790742 DOI: 10.1158/1535-7163.mct-08-0265] [Cited by in Crossref: 129] [Cited by in F6Publishing: 66] [Article Influence: 9.2] [Reference Citation Analysis]
31 Li L, Yeo W. Value of quality of life analysis in liver cancer: A clinician’s perspective. World J Hepatol 2017; 9(20): 867-883 [PMID: 28804570 DOI: 10.4254/wjh.v9.i20.867] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
32 Samonakis DN, Notas G, Christodoulakis N, Kouroumalis EA. Mechanisms of action and resistance of somatostatin analogues for the treatment of hepatocellular carcinoma: a message not well taken. Dig Dis Sci. 2008;53:2359-2365. [PMID: 18273705 DOI: 10.1007/s10620-007-0175-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
33 Cabibbo G, Antonucci M, Genco C. Update on new approaches in the management of hepatocellular carcinoma. Hepat Med 2010;2:163-73. [PMID: 24367214 DOI: 10.2147/HMER.S7132] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
34 Su L, Xu W. Peptidomimetics and metalloprotease inhibitors as anticancer drugs. Sci China Ser B-Chem 2009;52:535-48. [DOI: 10.1007/s11426-009-0040-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
35 Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med. 2011;9:171. [PMID: 21985599 DOI: 10.1186/1479-5876-9-171] [Cited by in Crossref: 143] [Cited by in F6Publishing: 134] [Article Influence: 13.0] [Reference Citation Analysis]
36 Pivonello C, De Martino MC, Negri M, Cuomo G, Cariati F, Izzo F, Colao A, Pivonello R. The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. Infect Agent Cancer 2014;9:27. [PMID: 25225571 DOI: 10.1186/1750-9378-9-27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
37 Sanoff HK, Kim R, Ivanova A, Alistar A, McRee AJ, O’Neil BH. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma. Invest New Drugs. 2015;33:505-509. [PMID: 25613083 DOI: 10.1007/s10637-015-0209-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
38 Liu Y, Jiang L, Mu Y. Somatostatin receptor subtypes 2 and 5 are associated with better survival in operable hepatitis B-related hepatocellular carcinoma following octreotide long-acting release treatment. Oncol Lett 2013;6:821-8. [PMID: 24137418 DOI: 10.3892/ol.2013.1435] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
39 Guo TK, Hao XY, Ma B, Yang KH, Li YP, Li HL, Gu YH, Cai H, Liu YL, Li Y, Zhan WP. Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials. J Cancer Res Clin Oncol 2009;135:1685-92. [PMID: 19536563 DOI: 10.1007/s00432-009-0615-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
40 Berardi R, Morgese F, Torniai M, Savini A, Partelli S, Rinaldi S, Caramanti M, Ferrini C, Falconi M, Cascinu S. Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World J Gastrointest Oncol 2016; 8(4): 389-401 [PMID: 27096034 DOI: 10.4251/wjgo.v8.i4.389] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
41 Wohlleber K, Heger P, Probst P, Engel C, Diener MK, Mihaljevic AL. Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies. Qual Life Res 2021;30:2429-66. [PMID: 34283381 DOI: 10.1007/s11136-021-02810-8] [Reference Citation Analysis]